Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
19 January 2023 | Story Gerda-Marié van Rooyen | Photo Unsplash
One is never too old to learn, and continuous learning and upskilling is vital for those who want to remain career fit. The UFS offers various courses that are vocation-specific and delivered by experts.

While prospective students are looking forward to starting their tertiary education, a few older, more experienced graduates who have been capped at the December 2022 graduation ceremonies, prove that you are never too old to get an extra qualification.

In the words of the legendary entrepreneur and industrial designer, Steve Jobs: "There is always one more thing to learn." Cherene Pienaar (age 38), a journalist and second-year master’s degree student in Creative Writing at the University of the Free State (UFS), agrees: “I want to make the most of my time on earth and grow personally.”
 
Success depends on continuous learning

“Upskilling and re-skilling through continuous learning is no longer a luxury. It is a survival strategy,” says Belinda Janeke, Head of Career Services in the Division of Student Affairs. She says contexts of traditional vocations are changing with the inclusion of technology. “Apart from staying relevant, the biological and psychological benefits of learning are also scientifically backed; an active mind is good for you.”
 
Shirly Hyland, Director of the Kovsie Phahamisa Academy (KPHA) for Short Learning Programmes (SLP), says lifelong learning builds skills and knowledge and enhances the social inclusion, active citizenship, and personal development of individuals. "Even if SLPs may not necessarily lead to a formal Higher Education Qualifications Sub-Framework (HEQSF) qualification, it places lifelong learners at a competitive edge for employability. Persons who engage in lifelong learning are at the forefront of their profession and remain competitive.” 
 
Staying and being relevant

Participants enrolling for an SLP can rest assured, knowing that course material is fresh and relevant, as the KPHA embarks on a desktop study to determine the relevance, marketability, and competitiveness before a suggested SLP gets approved. Hyland says the UFS offers SLPs that are purposeful and in time for the needs of the relevant profession, industry, or society. Programmes are offered at affordable prices and encompass the top academic expertise at the UFS. “Every SLP gets created for professional development, professionals wishing to re-skill themselves to remain current and competitive, or young adults who wish to upskill themselves to become (more) employable.” 
 
Different options available

Hyland explains that lifelong learning can take on different formats, allowing innovation in content, design, offering, and delivery. "The traditional classroom is no longer the foundation of learning. SLPs allow people from all walks of life access to part-time, relevant, flexible, and affordable education.”
 
Advantages of studying later in life

Janeke says older students may be more motivated and focused than 18-year-olds. “Most 18-year-olds experience vocation uncertainty. The pressure to pick a degree can cause them to study what others prefer, only to realise where their true passion lies later in life.” In contrast, older students bring experience, wisdom, and understanding to a programme. “They have often seen theory play out in practice and have a better view of abstract concepts and ideas. Due to their experience, they excel in a programme application or practical components.”
 
The UFS Career Services is like a finishing school for career readiness and offers a self-paced programme that covers self-knowledge and career exploration. “During the programme, students do an in-depth career exploration to ensure that their skills, values, and interests align with market offerings. A gap analysis helps them to obtain the skills they need, and a deep dive into career possibilities reveals different opportunities instead of being stuck on a one-track approach.” Janeke says their workshops and events focus on employability and connecting students with potential employers. “We have found that students need more than a qualification to contribute to the workspace. We aim to ensure that they will become employees of choice.”
 
What it takes

Hyland advises participants to be committed to the programme in order to be successful in any SLP. “Participants should ensure the SLP adds value to their lives – professionally and/or personally.” Other tips include reading documentation thoroughly, sticking to timelines provided, and keeping communication lines open with the programme owner when troubles arise.
  
Although financial constraints or family responsibilities may prevent (further) studies initially, these challenges can be overcome. “Once these barriers are removed, people may pursue their career dreams. Furthering one's studies will provide more than knowledge and skills.” Janeke advises prospective students to set aside a place and time for studies, create a support network and accountability group, and develop healthy habits. “If your studies are self-funded, budget your study and household costs – and pick your programme wisely.” 
 
Pienaar says getting an extra degree is possible despite having a full-time job, but it is probably more challenging when you have a family. “To pass on postgraduate level is still a job well done.”
 
Career Services can be contacted at career@ufs.ac.za .
For more information regarding short learning programmes, visit www.ufs.ac.za/kpa.
 

News Archive

Cardiology Unit involved in evaluation of drug for rare genetic disease
2013-01-04

Front from the left, are: Marinda Karsten (study coordinator and registered nurse),
Laumarie de Wet (clinical technologist), Charmaine Krahenbuhl (study coordinator and radiographer),
Lorinda de Meyer (administrator), Andonia Page (study coordinator and enrolled nurse);
back Dr Gideon Visagie (sub investigator), Dr Derick Aucamp (sub investigagtor),
Prof. Hennie Theron, (principal investigator) and Dr Wilhelm Herbst (sub investigator).
Photo: Supplied
09 January 2013


The Cardiology Research Unit at the University of the Free State (UFS) contributed largely to the evaluation of the drug Juxtapid (lomitapide), which was developed by the Aegerion pharmaceutical company and approved by the FDA (Federal Drug Administration). Together with countries such as die USA, Canada and Italy, the UFS’ Unit recruited and evaluated the most patients (5 of 29) for the study since 2008.  

The drug was evaluated in persons with so-called familial homozygous hypercholesterolemia (HoFH).  

Following its approval by the FDA, Juxtapid is now a new treatment option for patients suffering from HoFH. The drug operates in a unique way which brings about dramatic improvements in cholesterol counts.  

According to Prof. Hennie Theron, Associate Professor in the Department of Cardiology at the UFS and Head of the Cardiology Contract Research Unit, HoFH is a serious, rare genetic disease which affects the function of the receptor responsible for the removal of low-density lipoprotein cholesterol (LDL-C) (“bad” cholesterol) from the body. Damage to the LDL receptor function leads to extremely high levels of blood cholesterol. HoFH patients often develop premature and progressive atherosclerosis, which is a narrowing or blockage of the arteries.  

“HoFH is a genetically transmitted disease and the most severe form of hypercholesterolemia. Patients often need a coronary artery bypass or/and aortic valve replacement before the age of 20. Mortality is extremely high and death often occurs before the third decade of life. Existing conventional cholesterol-lowering medication is unsuccessful in achieving normal target cholesterol values in this group of patients.  

“The only modality for treatment is plasmapheresis (similar to dialysis in patients with renal failure). Even with this type of therapy the results are relatively unsatisfactory because it is very expensive and the plasmapheresis has to be performed on a regular basis.  

“The drug Juxtapid, as currently evaluated, has led to a dramatic reduction in cholesterol values and normal values were achieved in several people. No existing drug is nearly as effective.  

“The drug represents a breakthrough in the treatment of familial homozygous hypercholesterolemia. The fact that it has been approved by the FDA, gives further impetus to the findings,” says Prof. Theron.  

In future further evaluation will be performed in other forms of hypocholesterolemia.  

According to Prof. Theron, the findings of the study, as well as the recent successful FDA evaluation, once again confirms the fact that the UFS’ Cardiology Contract Research Unit is doing outstanding work.  

Since its inception in 1992, the Unit has already been involved in more than 60 multi-centre, international phase 2 and 3 drug studies. Several of these studies, including the abovementioned study, really affected the way in which cardiology functions.  

The UFS’ Cardiology Contract Research Unit is being recognised nationally and internationally for its high quality of work and is constantly approached for their involvement in new studies.  

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept